Intelligent PTH Compound Administration Systems
Legal Citation
Summary of the Inventive Concept
A synergistic system integrating PTH compounds with AI, IoT, blockchain, and nanomaterials to optimize treatment outcomes for hypoparathyroidism patients
Background and Problem Solved
The original patent disclosed PTH compounds with low peak-to-trough ratios, but limitations in administration intervals and dosing optimization hindered treatment effectiveness. This inventive concept addresses these limitations by incorporating advanced technologies to create a more personalized, efficient, and effective treatment system
Detailed Description of the Inventive Concept
The system comprises a PTH compound, a blockchain-based tracking system for monitoring administration intervals, and an AI-powered dosing algorithm for optimizing peak to trough ratios. Additionally, the system may include a nanomaterial-based delivery system, IoT-enabled wearable devices for real-time monitoring, and machine learning models for predicting patient response and personalizing treatment. The AI algorithm integrates patient data, pharmacokinetic profiles, and genomic information to adjust dosing in real-time, ensuring optimal treatment outcomes
Novelty and Inventive Step
The integration of AI, IoT, blockchain, and nanomaterials with PTH compounds creates a novel, non-obvious system that surpasses the original patent's limitations. The inventive step lies in the synergistic combination of these technologies to optimize treatment outcomes, providing a more effective and personalized approach to hypoparathyroidism treatment
Alternative Embodiments and Variations
Alternative embodiments may include different AI algorithms, varying nanomaterial designs, or alternative IoT-enabled devices. The system may also be adapted for other diseases or conditions requiring personalized treatment, expanding the scope of the inventive concept
Potential Commercial Applications and Market
The intelligent PTH compound administration system has significant commercial potential in the pharmaceutical and healthcare industries, offering a more effective and personalized approach to treating hypoparathyroidism. The system may be marketed as a premium product, targeting hospitals, clinics, and healthcare providers seeking to improve patient outcomes and reduce treatment costs
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/29 |
| A | A61 | A61K9/00 |
| A | A61 | A61K47/34 |
| A | A61 | A61K47/60 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically peptide-based therapeutic delivery systems for endocrine disorders, with expertise in pharmacokinetics, drug formulation, and personalized medicine technologies
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences or bioengineering, experienced in drug delivery systems, machine learning applications in healthcare, and understanding of complex biological monitoring technologies
Obviousness Rationale
A PHOSITA would recognize that the integration of AI, IoT, and nanomaterial technologies with existing PTH compound delivery represents a predictable extension of known personalized medicine approaches. The core pharmaceutical composition remains fundamentally consistent with the source patent, while the added technological layers provide incremental improvements in monitoring and administration. These technological enhancements represent standard design choices in modern pharmaceutical development that would be obvious to a skilled practitioner seeking to optimize treatment outcomes.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,603 |
|---|---|
| Title | PTH compounds with low peak-to-trough ratios |
| Assignee(s) | ASCENDIS PHARMA BONE DISEASES A/S |